Immunotherapy has become an essential pillar for cancer treatment, and the drug development space continues to attract numerous organizations that aim to transform scientific innovation into practice-changing cancer drugs. In the current analysis, we provide the latest update of the global immuno-oncology (IO) drug pipeline development, comparing our first survey conducted in September 2017 with our most recent survey conducted in August 2019.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Competing Interests
The authors declare no competing interests.